HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Psychotic Disorders (Schizoaffective Disorder)

Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)
Also Known As:
Schizoaffective Disorder; Psychotic Disorder; Schizophreniform Disorder; Psychoses; Disorder, Psychotic; Disorder, Schizoaffective; Schizoaffective Disorders; Psychosis; Brief Reactive Psychoses; Brief Reactive Psychosis; Disorder, Schizophreniform; Disorders, Psychotic; Disorders, Schizoaffective; Disorders, Schizophreniform; Psychoses, Brief Reactive; Reactive Psychoses, Brief; Reactive Psychosis, Brief; Psychosis, Brief Reactive; Schizophreniform Disorders
Networked: 21235 relevant articles (1376 outcomes, 3879 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Schizophrenia (Dementia Praecox)
2. Psychotic Disorders (Schizoaffective Disorder)
3. Parkinson Disease (Parkinson's Disease)
4. Dementia (Dementias)
5. Mania (Manias)

Experts

1. McGorry, Patrick D: 134 articles (10/2022 - 09/2002)
2. Murray, Robin M: 130 articles (04/2022 - 03/2004)
3. McGuire, Philip: 121 articles (12/2022 - 01/2007)
4. Crespo-Facorro, Benedicto: 112 articles (10/2022 - 08/2006)
5. Joober, Ridha: 95 articles (12/2022 - 12/2005)
6. Keshavan, Matcheri S: 85 articles (01/2022 - 01/2002)
7. de Haan, Lieuwe: 79 articles (06/2022 - 01/2003)
8. Arango, Celso: 77 articles (11/2022 - 11/2004)
9. Malla, Ashok: 76 articles (12/2022 - 08/2003)
10. Melle, Ingrid: 74 articles (01/2022 - 05/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Psychotic Disorders:
1. Antipsychotic Agents (Antipsychotics)IBA
2. Clozapine (Clozaril)FDA LinkGeneric
3. Risperidone (Risperdal Consta)FDA LinkGeneric
4. Polytetrafluoroethylene (Teflon)FDA Link
5. Olanzapine (Zyprexa)FDA Link
6. Quetiapine Fumarate (Seroquel)FDA Link
7. Aripiprazole (Abilify)FDA Link
10/01/2002 - "Most recently, aripiprazole, in early studies, appears to produce significant reductions in hPrl while maintaining therapeutic efficacy for psychosis."
07/01/2009 - "During combined treatment with mean doses of 22.9 mg of aripiprazole for 9.7 weeks, we assessed a small yet statistically not significant improvement of the psychotic disorder, whereas a marked reduction of obsessions and significant improvements of compulsions could be observed. "
01/01/2010 - "Efficacy of high-dose aripiprazole for treatment-resistant schizoaffective disorder: a case report."
11/01/2007 - "Aripiprazole 10 mg/day showed significantly greater improvements (mean change [2 x SD]) than placebo on the NPI-NH Psychosis Subscale (-6.87 [8.6] versus -5.13 [10.0]; F = 6.29, df = 1, 422, p = 0.013 by analysis of covariance [ANCOVA]); CGI-S (-0.72 [1.8] versus -0.46 [1.6]; F = 4.68, df = 1, 419, p = 0.031 [ANCOVA]); BPRS Total (-7.12 [18.4] versus -4.17 [21.6]; F = 4.72, df = 1, 399, p = 0.030 [ANCOVA]); BPRS Core (-3.07 [6.9] versus -1.74 [7.8]; F = 7.30, df = 1, 407, p = 0.007 [ANCOVA]); CMAI (-10.96 [22.6] versus -6.64 [28.6]; F = 5.23, df = 1, 410, p = 0.023 [ANCOVA]), and NPI-NH Psychosis response rate (65 versus 50%; chi(2) = 5.52, df = 1, p = 0.019 [CMH]). "
10/01/2005 - "In conclusion, aripiprazole showed similar improvements to placebo in psychotic symptoms as assessed by NPI Psychosis subscale scores, but significantly greater effects on BPRS Core and Psychosis assessments in community-living AD patients with psychosis. "
8. Pharmaceutical PreparationsIBA
9. Haloperidol (Haldol)FDA LinkGeneric
10. pimavanserinIBA

Therapies and Procedures

1. Therapeutics
2. Drug Therapy (Chemotherapy)
3. Injections
4. Secondary Prevention
5. Aftercare (After-Treatment)